REGULATED PRESS RELEASE published on 06/30/2025 at 22:30, 9 months 9 days ago Information on the Annual Financial Statements Biophytis delays publishing of 2024 annual accounts, aiming for release by July 7. The company focuses on treatments for age-related diseases Financial Statements Biophytis Age-related Diseases 2024 Annual Accounts Clinical-stage Biotechnology Company
PRESS RELEASE published on 06/30/2025 at 22:29, 9 months 9 days ago Information on the Annual Financial Statements Biophytis SA delays publication of 2024 annual accounts, aiming to release by July 7. The clinical-stage biotech company focuses on age-related disease treatments Biotechnology Company Clinical-stage Biophytis SA Age-related Diseases 2024 Annual Accounts
BRIEF published on 06/19/2025 at 23:05, 9 months 20 days ago Biophytis Temporarily Suspends Share Trading Biophytis Regulatory Compliance Financial Report Euronext Growth Share Suspension
REGULATED PRESS RELEASE published on 06/19/2025 at 23:00, 9 months 20 days ago Biophytis announces the temporary suspension of the trading of its shares Biophytis announces temporary suspension of trading shares on Euronext due to delayed financial report. Expected to resume after report publication. Company info included Biophytis Euronext Trading Financial Report Suspension
PRESS RELEASE published on 06/19/2025 at 22:59, 9 months 20 days ago Biophytis announces the temporary suspension of the trading of its shares Biophytis announces temporary suspension of trading of its shares by Euronext due to non-publication of annual financial report for 2024, expected to resume after report publication Biophytis Shares Euronext Trading Suspension
BRIEF published on 06/04/2025 at 07:05, 10 months 5 days ago Biophytis to Attend BIO International Convention in Boston Biophytis Biotechnology Partnerships BIO101 Convention
REGULATED PRESS RELEASE published on 06/04/2025 at 07:00, 10 months 5 days ago Biophytis announces its participation in the BIO International Convention from June 16 to 19 Biophytis announces participation in BIO International Convention from June 16 to 19, 2025 in Boston, USA. Focus on drug candidate BIO101 and potential partnerships Biophytis Biotechnology Partnerships BIO International Convention Drug Candidate
BRIEF published on 05/30/2025 at 22:05, 10 months 10 days ago Biophytis Delays 2024 Annual Financial Report Publication Financial Statements Biophytis Shareholder Meeting Age-related Diseases Audit Delay
REGULATED PRESS RELEASE published on 05/30/2025 at 22:00, 10 months 10 days ago Information on the Annual Financial Statements Biophytis postpones the publication of its 2024 annual financial statements due to technical complications in the audit process. The Company aims to complete the audit by the end of June 2025 Biophytis Audit Postponement 2024 Annual Financial Statements Technical Complications
PRESS RELEASE published on 05/30/2025 at 21:59, 10 months 10 days ago Information on the Annual Financial Statements Biophytis postpones 2024 annual financial statements publication due to technical audit issues, reschedules General Meeting of shareholders following legal procedures Shareholders Financial Statements Biophytis Meeting Audit
Published on 04/10/2026 at 02:15, 2 hours 21 minutes ago Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 3 hours 31 minutes ago Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 4 hours 36 minutes ago Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/09/2026 at 23:15, 5 hours 21 minutes ago Digi Power X Enters into Amended and Restated Sales Agreement
Published on 04/09/2026 at 22:00, 6 hours 36 minutes ago Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 21:01, 7 hours 35 minutes ago GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 20:03, 8 hours 32 minutes ago Annual General Meeting approves all proposals
Published on 04/09/2026 at 18:15, 10 hours 20 minutes ago REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 18:35, 10 hours 1 minute ago Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 15:57, 12 hours 38 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 21 hours 36 minutes ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 10 hours ago Publication of the 2025 Universal Registration Document
